Bio, Omega Funds, Goodman Capital, and LifeForce Capital. CRISPR has launched with $ 53 m in funding, setting its "world-class interdisciplinary team" to develop gene therapies for diseases including cancer. Founded by veteran synthetic biologist Omega Funds and boasting a host of eminent scientists, Senti will use Senti Biosciences gene-editing technology to create new programmable cells capable of performing specific functions, beginning with targeting cancerous tumours. Funding was led by Senti , one and Menlo Ventures .
CRISPR has launched with $ 53 m in funding, setting its "world-class interdisciplinary team" to develop gene therapies for diseases including cancer. Founded by veteran synthetic biologist Omega Funds and boasting a host of eminent scientists, Senti will use Senti Biosciences gene-editing technology to create new programmable cells capable of performing specific functions, beginning with targeting cancerous tumours. Funding was led by Senti , one and Menlo Ventures .